The Heart Whispers Before It Fails

What echo reveals about ATTR-CM before the diagnosis is missed. Join leading cardiology faculty for a focused session on recognizing, diagnosing and managing Transthyretin Cardiac Amyloidosis.

Date: 24th June 2026
Time and Format: 08:00 PM GMT +4 (UAE Time) · Virtual

Event starts in

00 Days

00 Hours

00 Minutes

00 Seconds

24th June 2026 · 08:00 PM GMT +4 (UAE Time)

Expert Faculty

Live Sessions

90 Min

Live and Interactive

CME

Accredited

Why attend

Listen to the heart. Look deeper.

Transthyretin Cardiac Amyloidosis is underrecognized and often missed until late. This session brings together expert faculty to sharpen early recognition, walk through noninvasive screening and diagnostic tests, and discuss practical management, so the heart is heard before it fails.

Early recognition

Spot the echo and clinical red flags that point to ATTR-CM sooner.

Accurate diagnosis

Noninvasive screening and diagnostic pathways that confirm ATTR-CM.

Better outcomes

Earlier suspicion and timely management improve the patient journey.

Meet the experts

Faculty

Moderator

Dr. Nooshin Bazargani

Consultant Cardiologist, Dubai Health Authority

Deputy Head of the Dubai Heart Centre

Dubai Hospital, UAE

Speaker

Dr. Arif Al Mulla

President, Pulmonary Hypertension Group of the Emirates Thoracic Society

Chief of Cardiology, Advanced Heart Failure and Pulmonary

Dubai Hospital, UAE

Programme

Agenda

24th June 2026 · 08:00 PM GMT +4 (UAE Time) · Virtual

Time Topic

8:00 to 8:05 PM

Opening Remarks

Dr. Nooshin Bazargani
8:05 to 8:25 PM

Introduction and Clinical Presentation of ATTR-CM

Dr. Nooshin Bazargani
8:25 to 9:15 PM

Noninvasive Screening and Diagnostic Tests of ATTR-CM

Dr. Arif Al Mulla
9:15 to 9:30 PM

Q and A

All Faculty

Reserve your place

Registration is quick and free. Secure your seat at this virtual ATTR-CM session and receive joining details by email.

CME accredited
Live faculty panel
No cost to attend

Supported by

Managed by